All In Biotech

Drug Trial Radar · NCT00492726

Therapy of Complicated Intra-Abdominal Infections With Moxifloxacin or Ertapenem

A Prospective, Randomized, Double-dummy, Double-blind, Multicenter Trial Comparing the Safety and Efficacy of Intravenous Moxifloxacin 400 mg IV QD 24 Hours to That of Ertapenem 1.0 g IV QD 24 Hours for 5 to 14 Days for the Treatment of Subjects With Complicated Intra-abdominal Infections (PROMISE Study)

Last checked: Nov 20, 2026Latest source record: Nov 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 804 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

804

Actual

Start

Jul 2006

Primary completion

Feb 2009

Study completion Feb 2009

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jun 27, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to compare the safety and efficacy of moxifloxacin to ertapenem in patients with intra-abdominal infections.

Conditions

  • Infection

Interventions

  • Moxifloxacin (Avelox, BAY12-8039)Drug

    Moxifloxacin, 400mg, administered intravenously once daily

  • Ertapenem intravenousDrug

    Active treatment: Ertapenem 1.0g, administered intravenously once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects Achieving Clinical Cure at Test of Cure (TOC) Visit in the Per Protocol PopulationTime frame: 21 to 28 days after completion of study drug therapy

Locations

52 sites in 14 countries. Site status is shown where the registry gives one.

  • Site not named

    Capital Federal, Argentina

  • Site not named

    Ciudadela, Buenos Aires, Argentina

  • Site not named

    De Febrero 3, Buenos Aires, Argentina

  • Site not named

    Merlo, Buenos Aires, Argentina

  • Site not named

    San Juan Bautista, Buenos Aires, Argentina

  • Site not named

    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina

  • Site not named

    Córdoba, Córdoba Province, Argentina

  • Site not named

    Mendoza, Mendoza Province, Argentina

  • Site not named

    Rosario, Santa Fe Province, Argentina

  • Site not named

    Bruxelles - Brussel, Belgium

  • Site not named

    Bruxelles - Brussel, Belgium

  • Site not named

    Ghent, Belgium

  • Site not named

    Pleven, Bulgaria

  • Site not named

    Rousse, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Kohtla-Järve, Estonia

  • Site not named

    Tallinn, Estonia

  • Site not named

    Tartu, Estonia

  • Site not named

    Amilly, France

  • Site not named

    Besançon, France

  • Site not named

    Heidelberg, Baden-Wurttemberg, Germany

  • Site not named

    Beeskow, Brandenburg, Germany

  • Site not named

    Hanover, Lower Saxony, Germany

  • Site not named

    Paderborn, North Rhine-Westphalia, Germany

  • Site not named

    Homburg, Saarland, Germany

  • Site not named

    Rio Patras, Greece

  • Site not named

    Haifa, Israel

  • Site not named

    Kfar Saba, Israel

  • Site not named

    Daugavpils, Latvia

  • Site not named

    Liepāja, Latvia

  • Site not named

    Rēzekne, Latvia

  • Site not named

    Riga, Latvia

  • Site not named

    Riga, Latvia

  • Site not named

    Valmiera, Latvia

  • Site not named

    Kaunas, Lithuania

  • Site not named

    Klaipėda, Lithuania

  • Site not named

    Vilnius, Lithuania

  • Site not named

    Vilnius, Lithuania

  • Site not named

    Brasov, Romania

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.